PMV Pharmaceuticals (PMVP) to Release Quarterly Earnings on Thursday

PMV Pharmaceuticals (NASDAQ:PMVP - Get Free Report) is anticipated to post its Q1 2025 quarterly earnings results before the market opens on Thursday, May 8th. Analysts expect PMV Pharmaceuticals to post earnings of ($0.37) per share for the quarter.

PMV Pharmaceuticals (NASDAQ:PMVP - Get Free Report) last issued its quarterly earnings results on Monday, March 3rd. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.08). On average, analysts expect PMV Pharmaceuticals to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

PMV Pharmaceuticals Stock Down 0.5 %

Shares of PMV Pharmaceuticals stock traded down $0.00 during trading on Tuesday, hitting $0.93. 83,895 shares of the stock traded hands, compared to its average volume of 244,754. The stock has a market cap of $48.52 million, a price-to-earnings ratio of -0.93 and a beta of 1.50. PMV Pharmaceuticals has a 52 week low of $0.82 and a 52 week high of $2.26. The firm's fifty day moving average is $1.11 and its 200-day moving average is $1.38.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a "buy" rating and set a $5.00 price target on shares of PMV Pharmaceuticals in a research report on Thursday, March 20th.

PMV Pharmaceuticals Company Profile

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function.